The Hepatitis B Virus Polymerase Mutation rtV173L Is Selected during Lamivudine Therapy and Enhances Viral Replication In Vitro

Journal of Virology

Volumn 77, Issue 21, 2003, Pages 11833-11841

  Delaney, William E ^a   Yang, Huiling ^a   Westland, Christopher E ^a   Das, Kalyan ^b,c   Arnold, Eddy ^b,c   Gibbs, Craig S ^a   Miller, Michael D ^a   Xiong, Shelly ^a  

^a GILEAD SCIENCES   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; FAMCICLOVIR; LAMIVUDINE; LEUCINE; PENCICLOVIR; RNA DIRECTED DNA POLYMERASE; VALINE;

AMINO ACID SUBSTITUTION; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VIRUS MUTATION; VIRUS REPLICATION;

2-AMINOPURINE; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; SELECTION (GENETICS); VIRUS REPLICATION;

EID: 0142092372     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.21.11833-11841.2003     Document Type: Article

References (40)

1. Allen, M. I., M. Deslauriers, C. W. Andrews, G. A. Tipples, K. A. Walters, D. L. Tyrrell, N. Brown, L. D. Condreay, et al. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677.
2. Aye, T. T., A. Bartholomeusz, T. Shaw, S. Bowden, A. Breschkin, J. McMillan, P. Angus, and S. Locarnini. 1997. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J. Hepatol. 26:1148-1153.
3. Bartholomew, M. M., R. W. Jansen, L. J. Jeffers, K. R. Reddy, L. C. Johnson, H. Bunzendahl, L. D. Condreay, A. G. Tzakis, E. R. Schiff, and N. A. Brown. 1997. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349:20-22.
4. Benhamou, Y., M. Bochet, V. Thibault, V. Calvez, M. H. Fievet, P. Vig, C. S. Gibbs, C. Brosgart, J. Fry, H. Namini, C. Katlama, and T. Poynard. 2001. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 358:718-723.
5. Boyer, P. L., H. Q. Gao, and S. H. Hughes. 1998. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob. Agents Chemother. 42:447-452.
6. Carman, W. F., C. Trautwein, F. J. van Deursen, K. Colman, E. Dornan, G. McIntyre, J. Waters, V. Kliem, R. Muller, H. C. Thomas, and M. P. Manns. 1996. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 24:489-493.
7. Carman, W. F., A. R. Zanetti, P. Karayiannis, J. Waters, G. Manzillo, E. Tanzi, A. J. Zuckerman, and H. C. Thomas. 1990. Vaccine-induced escape mutant of hepatitis B virus. Lancet 336:325-329.
8. Chayama, K., Y. Suzuki, M. Kobayashi, M. Kobayashi, A. Tsubota, M. Hashimoto, Y. Miyano, H. Koike, M. Kobayashi, I. Koida, Y. Arase, S. Saitoh, N. Murashima, K. Ikeda, and H. Kumada. 1998. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27:1711-1716.
9. Chin, R., T. Shaw, J. Torresi, V. Sozzi, C. Trautwein, T. Bock, M. Manns, H. Isom, P. Furman, and S. Locarnini. 2001. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil. Antimicrob. Agents Chemother. 45:2495-2501.
10. Cooley, L., A. Ayres, A. Bartholomeusz, S. Lewin, S. Crowe, A. Mijch, S. Locarnini, and J. Sasadeusz. 2003. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 17:1649-1657.
11. Cooreman, M. P., G. Leroux-Roels, and W. P. Paulij. 2001. Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J. Biomed. Sci. 8:237-247.
12. Das, K., X. Xiong, H. Yang, C. E. Westland, C. S. Gibbs, S. G. Sarafianos, and E. Arnold. 2001. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J. Virol. 75:4771-4779.
13. Delaney, W. E., IV, A. Bartholomeusz, and S. A. Locarnini. 2002. Evolving therapies for the treatment of chronic hepatitis B virus infection. Expert Opin. Investig. Drugs 11:169-187.
14. Delaney, W. E., IV, R. Edwards, D. Colledge, T. Shaw, J. Torresi, T. G. Miller, H. C. Isom, C. T. Bock, M. P. Manns, C. Trautwein, and S. Locarnini. 2001. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob. Agents Chemother. 45:1705-1713.
15. Delaney, W. E., IV, S. Locarnini, and T. Shaw. 2001. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir. Chem. Chemother. 12:1-35.
16. de Man, R. A., P. Marcellin, F. Habal, P. Desmond, T. Wright, T. Rose, R. Jurewicz, and C. Young. 2000. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology 32:413-417.
17. Gunther, S., F. von Breunig, T. Santantonio, M. C. Jung, G. B. Gaeta, L. Fischer, M. Sterneck, and H. Will. 1999. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. J. Hepatol. 30:749-754.
18. Iversen, A. K., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
19. Kleim, J. P., M. Rosner, I. Winkler, A. Paessens, R. Kirsch, Y. Hsiou, E. Arnold, and G. Riess. 1996. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74→Val of Ile and Val-75→Leu of Ile) HIV-1 mutants. Proc. Natl. Acad. Sci. USA 93:34-38.
20. Lai, C. L., J. Dienstag, E. Schiff, N. W. Leung, M. Atkins, C. Hunt, N. Brown, M. Woessner, R. Boehme, and L. Condreay. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36:687-696.
21. Ling, R., D. Mutimer, M. Ahmed, E. H. Boxall, E. Elias, G. M. Dusheiko, and T. J. Harrison. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711-713.
22. Melegari, M., P. P. Scaglioni, and J. R. Wands. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
23. Mutimer, D., D. Pillay, P. Cook, D. Ratcliffe, K. O'Donnell, D. Dowling, J. Shaw, E. Elias, and P. A. Cane. 2000. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. J. Infect. Dis. 181:713-716.
24. Nijhuis, M., R. Schuurman, D. de Jong, J. Erickson, E. Gustchina, J. Albert, P. Schipper, S. Gulnik, and C. A. Boucher. 1999. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13:2349-2359.
25. Olivares, I., V. Sanchez-Merino, M. A. Martinez, E. Domingo, C. Lopez-Galindez, and L. Menendez-Arias. 1999. Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity. J. Virol. 73:6293-6298.
26. Ono, S. K., N. Kato, Y. Shiratori, J. Kato, T. Goto, R. F. Schinazi, F. J. Carrilho, and M. Omata. 2001. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J. Clin. Investig. 107:449-455.
27. Ono-Nita, S. K., N. Kato, Y. Shiratori, T. Masaki, K. H. Lan, F. J. Carrilho, and M. Omata. 1999. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection. Hepatology 29:939-945.
28. Ono-Nita, S. K., N. Kato, Y. Shiratori, H. Yoshida, J. Kato, T. Goto, R. F. Schinazi, F. J. Carrilho, and M. Omata. 2000. Influence of B domain mutation (L528M) of the hepatitis B virus polymerase on replication ability and resistance to nucleoside analogues. Hepatology 32:393A.
29. Pelemans, H., R. Esnouf, K. L. Min, M. Parniak, E. De Clercq, and J. Balzarini. 2001. Mutations at amino acid positions 63, 189, and 396 of human immunodeficiency virus type 1 reverse transcriptase (RT) partially restore the DNA polymerase activity of a Trp229Tyr mutant RT. Virology 287:143-150.
30. Pichoud, C., B. Seigneres, Z. Wang, C. Trepo, and F. Zoulim. 1999. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 29:230-237.
31. Resch, W., R. Ziermann, N. Parkin, A. Gamarnik, and R. Swanstrom. 2002. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly. J. Virol. 76:8659-8666.
32. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Analysis and cloning of eukaryotic genomic DNA, p. 9.1-9.62. In N. Ford, C. Nolan, and M. Ferguson (ed.), Molecular cloning, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
33. Seigneres, B., C. Pichoud, S. S. Ahmed, O., Hantz, C. Trepo, and F. Zoulim. 2000. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B. J. Infect. Dis. 181:1221-1233.
34. Stuyver, L. J., S. A. Locarnini, A. Lok, D. D. Richman, W. F. Carman, J. L. Dienstag, and R. F. Schinazi. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757.
35. Tillmann, H. L., C. Trautwein, T. Bock, K. H. Boker, E. Jackel, M. Glowienka, K. Oldhafer, I. Bruns, J. Gauthier, L. D. Condreay, H. R. Raab, and M. P. Manns. 1999. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 30:244-256.
36. Torresi, J., L. Earnest-Silveira, G. Deliyannis, K. Edgtton, H. Zhuang, S. A. Locarnini, J. Fyfe, T. Sozzi, and D. C. Jackson. 2002. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293:305-313.
37. Westland, C., H. Yang, W. Delaney IV, C. Gibbs, M. Miller, M. Wulfsohn, J. Fry, C. Brosgart, and S. Xiong. 2003. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 38:96-103.
38. Xiong, X., H. Yang, C. E. Westland, R. Zou, and C. S. Gibbs. 2000. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 31:219-224.
39. Yang, H., C. Westland, W. E. Delaney IV, V. Ho, M. D. Miller, C. S. Gibbs, J. Fry, C. L. Brosgart, and S. Xiong. 2001. Resistance monitoring in chronic hepatitis B patients exposed to adefovir dipivoxil for 72 to 136 weeks. Hepatology 34:316A.
40. Yang, H., C. E. Westland, W. E. Delaney IV, E. J. Heathcote, V. Ho, J. Fry, C. Brosgart, C. S. Gibbs, M. D. Miller, and S. Xiong. 2002. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 36:464-473.